Luke Barnard, MD
Glaucoma Specialist · la Mesa, CANPI 1710543111
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,717, 6.9 times the $396 reported in 2023. That places this record below the midpoint for glaucoma specialist clinicians in CA, where the typical reported total is $4,143.
Across 77 payments — averaging $53.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$685
- Bausch & Lomb Americas Inc.$675
- Glaukos Corporation$589
- Alcon$436
- Tarsus Pharmaceuticals, Inc.$345
- Genentech USA, Inc.$294
- plus $1K from 8 others
What the payments were for
- Food & beverage$4,143100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 12 | $685 |
| Bausch & Lomb Americas Inc. | 14 | $675 |
| Glaukos Corporation | 6 | $589 |
| Alcon | 9 | $436 |
| Tarsus Pharmaceuticals, Inc. | 11 | $345 |
| Genentech USA, Inc. | 2 | $294 |
| Rxsight Inc | 3 | $282 |
| AbbVie | 5 | $217 |
| Sight Sciences, Inc. | 6 | $200 |
| Mallinckrodt Hospital Products Inc. | 3 | $195 |
| GSK | 1 | $93 |
| Sun Pharmaceutical Industries Inc. | 3 | $81 |
| NEW World Medical,inc. | 1 | $28 |
| Oyster Point Pharma, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$334
- VABYSMO$294
- ENVISTA ENVY IOL$293
- RXSIGHT CONTACT LENS$260
- RXSIGHT INJECTOR CARTRIDGE$260
- RXSIGHT INJECTOR HANDPIECE$260
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$260
- iDose$201
- iDoseTR$200
- STELLARIS$178
- Otezla$147
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$135
- Clareon$135
- ACTHAR$127
- LIGHT ADJUSTABLE LENS (LAL)$125
- XDEMVY$122
- iStent Trabecular Micro-Bypass System Model iS3$120
- enVista MX60 IOL$117
How this compares
$4,143 in reported general payments places this provider in the 50th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 14 | $12,223 |
| RhopressaNetarsudil Mesylate | 27 | $12,057 |
| LumiganBimatoprost | 25 | $11,532 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $11,325 |
| XiidraLifitegrast | 11 | $10,819 |
| Brimonidine Tartrate | 98 | $7,406 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 25 | $5,543 |
| Prednisolone Acetate | 95 | $4,287 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 21 | $3,299 |
| Latanoprost | 331 | $2,887 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 17 | $2,308 |
| Timolol Maleate | 108 | $2,274 |
| Travoprost | 21 | $2,267 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 123 | $1,619 |
| MoxifloxacinMoxifloxacin Hcl | 42 | $811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $217 | $23,75539 claims |
| Bausch & Lomb Americas Inc.Xiidra | $675 | $10,81911 claims |
| AlconSimbrinza | $436 | $5,54325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in la Mesa
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
- Jeffrey GoldbergStanford$57K
- Valentina LozanoCulver City$51K
- Sameh MosaedIrvine$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.